| Publications | PubMed=3855324; DOI=10.1288/00005537-198501000-00012
Baker S.R.
An in vivo model for squamous cell carcinoma of the head and neck.
Laryngoscope 95:43-56(1985) DOI=10.1016/B978-0-12-333530-2.50007-1
Carey T.E.
Head and neck tumor cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994) PubMed=12884349; DOI=10.1002/hed.10274
Bradford C.R., Zhu S.-B., Ogawa H., Ogawa T., Ubell M., Narayan A., Johnson G., Wolf G.T., Fisher S.G., Carey T.E.
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Head Neck 25:654-661(2003) PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007) PubMed=18006756; DOI=10.1158/1078-0432.CCR-07-1591
Friedman J., Nottingham L., Duggal P., Pernas F.G., Yan B., Yang X.-P., Chen Z., Van Waes C.
Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
Clin. Cancer Res. 13:6568-6578(2007) PubMed=19760794; DOI=10.1002/hed.21198
Brenner J.C., Graham M.P., Kumar B., Saunders L.M., Kupfer R., Lyons R.H., Bradford C.R., Carey T.E.
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines.
Head Neck 32:417-426(2010) PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011) PubMed=23613873; DOI=10.1371/journal.pone.0061555
Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A., Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
PLoS ONE 8:E61555-E61555(2013) PubMed=26045983
Ziemann F., Arenz A., Preising S., Wittekindt C., Klussmann J.P., Engenhart-Cabillic R., Wittig A.
Increased sensitivity of HPV-positive head and neck cancer cell lines to X-irradiation +/- cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis.
Am. J. Cancer Res. 5:1017-1031(2015) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017) PubMed=29156801; DOI=10.18632/oncotarget.21174
Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y., Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.
Oncotarget 8:86369-86383(2017) PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004
van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I., Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.
Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
Oral Oncol. 98:53-61(2019) PubMed=33802339; DOI=10.3390/cancers13051069
Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.
Genotyping and characterization of HPV status, hypoxia, and radiosensitivity in 22 head and neck cancer cell lines.
Cancers (Basel) 13:1069.1-1069.12(2021) |
|---|
